2 terminated, 1 active not recruiting, 1 completed, 1 recruiting. 4 Phase 1, 3 Phase 2, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Terminated 2, Active not recruiting 1, Completed 1 |
| Phase 2 | 3 | Terminated 2, Active not recruiting 1 |
| Not applicable | 1 | Recruiting 1 |
Follow Mesothelioma Peritoneum: new trials by email Literature Review of Mesothelioma Peritoneum trials Research Report on Mesothelioma Peritoneum
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer TC-510, Fludarabine, Cyclophosphamide - Mesothelioma, Mesotheliomas Pleural | Phase 1 / Phase 2 | Terminated | TCR2 Therapeutics | 14 | 2022-06-21 | 2026-07-13 |
| Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis Cardiac coherence, Standard care - Peritoneal Carcinomatosis, Pseudomyxoma Peritonei | Not applicable | Recruiting | Institut du Cancer de Montpellier - Val d'Aurelle | 60 | 2021-09-21 | 2026-01-16 |
| A Pilot Study to Explore the Role of Gut Flora in Metastatic Mesothelioma No intervention - Mesothelioma, Mesothelioma Malignant | Withdrawn | ProgenaBiome | 2020-03-02 | 2025-06-05 | ||
| Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer gavo-cel, fludarabine, cyclophosphamide - Mesothelioma, Mesothelioma, Malignant | Phase 1 / Phase 2 | Active not recruiting | TCR2 Therapeutics | 57 | 2019-04-15 | 2025-08-27 |
| CAR T Cells in Mesothelin Expressing Cancers huCART-meso cells - Lung Adenocarcinoma, Ovarian Cancer | Phase 1 | Completed | University of Pennsylvania | 65 | 2017-04-06 | 2025-04-29 |
Mesothelioma, Malignant (5) · Ovarian Neoplasms (4) · Carcinoma, Non-Small-Cell Lung (3) · Mesothelioma (3) · Cholangiocarcinoma (2) · Colorectal Neoplasms (2) · Adenocarcinoma of Lung (1) · Breast Neoplasms (1) · Diffuse Intrinsic Pontine Glioma (1) · Endometrial Neoplasms (1) · Esophageal Neoplasms (1) · Fallopian Tube Neoplasms (1) · Glioma (1) · Head and Neck Neoplasms (1) · Melanoma (1)
Neoplasms by Histologic Type (6) · Neoplasms by Site (6) · Neoplasms, Glandular and Epithelial (6) · Adenocarcinoma (5) · Adenoma (5) · Carcinoma (5) · Lung Diseases (5) · Lung Neoplasms (5) · Neoplasms (5) · Neoplasms, Mesothelial (5) · Pleural Neoplasms (5) · Respiratory Tract Diseases (5) · Respiratory Tract Neoplasms (5) · Thoracic Neoplasms (5) · Adnexal Diseases (4)
Cyclophosphamide (2) · fludarabine (2) · Ipilimumab (1) · Nivolumab (1) · Standard of Care (1)
TCR2 Therapeutics (2) · Aminex Therapeutics, Inc. (1) · Institut du Cancer de Montpellier - Val d'Aurelle (1) · ProgenaBiome (1) · University of Pennsylvania (1)
United States (5) · Australia (1) · Canada (1) · France (1)
Estelle Guerdoux-Ninot, MD (1) · Janos L Tanyi, MD, PhD (1) · Michael Armstrong, MD (1) · Sabine Hazan, MD (1) · Sue Lee, MD (1)